| ［1］ |
Gottlieb AB, Chamian F, Masud S, et al. TNF inhibition rapidly down⁃regulates multiple proinflammatory pathways in psoriasis plaques［J］. J Immunol, 2005, 175（4）: 2721⁃2729. DOI: 10.4049/jimmunol.175.4.2721.
|
| ［2］ |
Kimber I, Cumberbatch M, Dearman RJ, et al. Cytokines and chemokines in the initiation and regulation of epidermal Langerhans cell mobilization［J］. Br J Dermatol, 2000, 142（3）: 401⁃412. DOI: 10.1046/j.1365⁃2133.2000.03349.x.
|
| ［3］ |
Langley RG, Strober BE, Gu Y, et al. Benefit⁃risk assessment of tumour necrosis factor antagonists in the treatment of psoriasis［J］. Br J Dermatol, 2010, 162（6）: 1349⁃1358. DOI: 10.1111/j.1365⁃2133.2010.09707.x.
|
| ［4］ |
Ahmad K, Rogers S. Three years′ experience with infliximab in recalcitrant psoriasis［J］. Clin Exp Dermatol, 2006, 31（5）: 630⁃633. DOI: 10.1111/j.1365⁃2230.2006.02170.x.
|
| ［5］ |
Warren RB, Brown BC, Lavery D, et al. Biologic therapies for psoriasis: practical experience in a U.K. tertiary referral centre［J］. Br J Dermatol, 2009, 160（1）: 162⁃169. DOI: 10.1111/j.1365⁃2133.2008.08865.x.
|
| ［6］ |
余晓玲, 晋红中. 英夫利西单抗治疗关节病性银屑病进展［J］. 中华皮肤科杂志, 2014, 47（3）: 223⁃225. DOI: 10.3760/cma.j.issn.0412⁃4030.2014.03.023.
|
|
Yu XL, Jin HZ. Infliximab for the treatment of psoriatic arthropathica: an update［J］. Chin J Dermatol, 2014, 47（3）: 223⁃225. DOI: 10.3760/cma.j.issn.0412⁃4030.2014.03.023.
|
| ［7］ |
Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate⁃to⁃severe plaque psoriasis［J］. J Am Acad Dermatol, 2007, 56（1）: 31. DOI: 10.1016/j.jaad.2006.07.017.
|
| ［8］ |
张堂德, 李琳琳, 罗妙璇. 英夫利西单抗治疗寻常性银屑病七例［J］. 中华皮肤科杂志, 2015, 48（6）: 438⁃439. DOI: 10.3760/cma.j.issn.0412⁃4030.2015.06.024.
|
|
Zhang DT, Li LL, Luo MX. Infliximab for the treatment of seven patients with psoriasis vulgaris［J］. Chin J Dermatol, 2015, 48（6）: 438⁃439. DOI: 10.3760/cma.j.issn.0412⁃4030.2015.06.024.
|
| ［9］ |
Fabroni C, Gori A, Troiano M, et al. Infliximab efficacy in nail psoriasis. A retrospective study in 48 patients［J］. J Eur Acad Dermatol Venereol, 2011, 25（5）: 549⁃553. DOI: 10.1111/j.1468⁃3083.2010.03826.x.
|
| ［10］ |
Gómez⁃Reino JJ, Carmona L, Angel Descalzo M, et al. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection［J］. Arthritis Rheum, 2007, 57（5）: 756⁃761. DOI: 10.1002/art.22768.
|
